Advertisement
AMGN vs PFE
Which Stock Would AI Choose? Amgen (AMGN) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Amgen (AMGN) has demonstrated stronger relative price momentum in recent months, supported by a robust biologics pipeline and diversification into rare diseases.
- Pfizer (PFE) continues to navigate a post-pandemic revenue reset, with declining COVID-19 product sales weighing on top-line growth and investor sentiment.
- Amgen's obesity and inflammation drug candidates represent significant growth catalysts, while Pfizer has leaned heavily on acquisitions and cost-cutting to stabilize its outlook.
- Both companies offer attractive dividend yields, but Amgen's earnings trajectory appears more consistent in the current environment compared to Pfizer's transitional phase.
- From a market positioning perspective, Amgen's pipeline momentum and diversified portfolio may offer greater near-term appeal, while Pfizer's deep restructuring could create longer-term value for patient investors.
- AI-driven analysis tools, such as those from Tickeron, increasingly factor in trend consistency and catalyst clarity when evaluating stocks like AMGN and PFE side by side.
Introduction
Why compare AMGN and PFE? Both are pharmaceutical giants with decades of history, generous dividends, and massive global footprints. Yet in 2025 and heading into 2026, they find themselves on meaningfully different trajectories. Amgen has been riding a wave of pipeline optimism, particularly in obesity and inflammation, while Pfizer has been working through a difficult post-COVID normalization. This stock comparison is relevant for income-oriented investors evaluating dividend sustainability, growth investors assessing pipeline potential, and traders scanning for relative strength signals in the large-cap healthcare sector. Understanding where each company stands today can help clarify how market sentiment and fundamentals are shaping their respective paths forward.
AMGN Overview and Recent Performance
AMGN, headquartered in Thousand Oaks, California, is one of the world's largest independent biotechnology companies, with a portfolio spanning oncology, cardiovascular disease, inflammation, and bone health. Its flagship products include Prolia, Otezla, Enbrel, and Repatha, which together generate tens of billions in annual revenue.
In recent weeks, Amgen's stock has shown notable resilience compared to the broader healthcare sector. Investor enthusiasm has been fueled by growing confidence in MariTide, its investigational obesity treatment, which targets the same GLP-1 (glucagon-like peptide-1) pathway that has transformed the weight-loss drug market. Amgen's approach, which involves less frequent dosing, has been closely watched by Wall Street as a potential differentiator. Additionally, Amgen's acquisition of Horizon Therapeutics has expanded its rare-disease footprint, adding blockbuster drug Tepezza to its revenue base. Recent quarterly results showed solid operational performance, with management raising guidance amid improving cost efficiencies. The stock has generally held its ground as a defensive play with growth catalysts embedded in its pipeline.
PFE Overview and Recent Performance
PFE, based in New York City, ranks among the largest pharmaceutical companies globally, with a diversified portfolio across vaccines, oncology, immunology, and rare diseases. The company shot to unprecedented prominence during the COVID-19 pandemic with its Comirnaty vaccine and Paxlovid antiviral treatment, which together generated over $100 billion in peak-year revenue.
The post-pandemic era has proved challenging. In recent months, Pfizer's stock has struggled to find firm footing as COVID-product revenues have fallen sharply from their peak, creating tough year-over-year comparisons. The company has responded aggressively — launching a multi-billion-dollar cost-cutting program, streamlining operations, and deploying acquisition-driven growth, most notably the $43 billion acquisition of Seagen to bolster its oncology pipeline. Recent earnings reports have shown signs of stabilization, with non-COVID revenues growing modestly, yet the stock has continued to face skepticism from investors questioning whether the Seagen integration and pipeline assets can fully offset the COVID revenue cliff. Pfizer's dividend remains a key attraction, but the stock's relative performance reflects lingering uncertainty around its growth transition.
Trending AI Robots
In a market environment where pharmaceutical stocks can shift rapidly on clinical trial results, FDA (U.S. Food and Drug Administration) decisions, and macroeconomic sentiment, AI-powered trading tools are gaining attention for their ability to process vast amounts of data in real time. Tickeron's Trending AI Robots page showcases a curated selection of the platform's most relevant AI trading bots — handpicked from hundreds that trade thousands of tickers — based on their alignment with current market conditions. These bots employ varied trading styles including swing trading, trend following, and momentum-based strategies, with some achieving win rates above 65% and annualized returns exceeding 20% in back-tested environments. Each bot operates with distinct parameters, timeframes, and ticker baskets, offering traders a range of approaches suited to different risk profiles. Explore the Trending AI Robots page to see which strategies are being highlighted for today's market.
Head-to-Head Comparison
When comparing AMGN and PFE directly, several key contrasts emerge:
Business Model: Amgen operates largely as a pure-play biotechnology company focused on large-molecule biologics, with higher margins and entrenched franchises. Pfizer combines small-molecule pharmaceuticals, vaccines, and an expanding oncology presence following the Seagen acquisition. Amgen's model is generally seen as more focused, while Pfizer's breadth offers diversification but adds complexity.
Growth Drivers: Amgen's near-term catalysts center on obesity (MariTide), rare disease (Tepezza), and biosimilars. Pfizer is betting heavily on oncology via Seagen's antibody-drug conjugate (ADC) technology and its RSV (respiratory syncytial virus) vaccine franchise. The market currently views Amgen's pipeline as nearer to potential inflection points.
Recent Momentum: Amgen has maintained relatively steady upward momentum, supported by consistent earnings beats and pipeline updates. Pfizer has experienced choppier trading, with sentiment weighed down by declining COVID revenues despite restructuring progress.
Risk Factors: Amgen faces patent cliffs on legacy products and competitive pressure in the obesity race. Pfizer's risks include Seagen integration execution, further COVID revenue erosion, and the need to demonstrate that its acquisition strategy will yield adequate returns on invested capital (ROIC).
Dividend Yield: Both are dividend aristocrats, with Pfizer typically offering a higher current yield — though this partly reflects the stock's price underperformance rather than purely superior dividend capacity.
Sector Exposure: Both are classified in the healthcare sector, but Amgen trades more like a growth-biotech hybrid, whereas Pfizer behaves closer to a value-pharmaceutical stock in the current cycle.
Tickeron AI Verdict
Based on observable factors such as trend consistency, pipeline catalyst clarity, and relative market positioning, Tickeron's AI-driven analysis would likely favor AMGN over PFE in the current environment. Amgen has demonstrated steadier price momentum, a more concentrated set of near-term growth drivers, and fewer transitional headwinds compared to Pfizer's ongoing restructuring narrative. While Pfizer's valuation may appear compelling on a price-to-earnings (P/E) basis and its oncology pivot could bear fruit over a multi-year horizon, the AI systems tend to weigh recent trend stability and catalyst visibility heavily — areas where Amgen currently holds an edge. This assessment is probabilistic in nature and reflects a snapshot of evolving market conditions rather than a permanent verdict.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and PFE is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- AMGN’s TA Score: 4 bullish, 5 bearish.
- PFE’s TA Score: 4 bullish, 6 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +0.80% price change this week, while PFE (@Pharmaceuticals: Major) price change was +3.64% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.78%. For the same industry, the average monthly price growth was +2.31%, and the average quarterly price growth was +5.54%.
Reported Earning Dates
AMGN is expected to report earnings on Aug 04, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.78% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | PFE | AMGN / PFE | |
| Capitalization | 197B | 141B | 140% |
| EBITDA | 16.7B | 17.2B | 97% |
| Gain YTD | 13.536 | 3.976 | 340% |
| P/E Ratio | 25.34 | 18.89 | 134% |
| Revenue | 37.2B | 63.3B | 59% |
| Total Cash | 12B | 13.1B | 92% |
| Total Debt | 57.3B | 63.7B | 90% |
AMGN | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 19 | 100 | |
SMR RATING 1..100 | 12 | 77 | |
PRICE GROWTH RATING 1..100 | 27 | 58 | |
P/E GROWTH RATING 1..100 | 59 | 42 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (4) in the Pharmaceuticals Major industry is in the same range as AMGN (9) in the Biotechnology industry. This means that PFE’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's Profit vs Risk Rating (19) in the Biotechnology industry is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is somewhat better than the same rating for PFE (77) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than PFE’s over the last 12 months.
AMGN's Price Growth Rating (27) in the Biotechnology industry is in the same range as PFE (58) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as AMGN (59) in the Biotechnology industry. This means that PFE’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | PFE | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 55% | 4 days ago 52% |
| Stochastic ODDS (%) | 4 days ago 54% | 4 days ago 53% |
| Momentum ODDS (%) | 4 days ago 52% | 4 days ago 52% |
| MACD ODDS (%) | 4 days ago 51% | 4 days ago 44% |
| TrendWeek ODDS (%) | 4 days ago 61% | 4 days ago 54% |
| TrendMonth ODDS (%) | 4 days ago 58% | 4 days ago 55% |
| Advances ODDS (%) | 5 days ago 59% | 5 days ago 54% |
| Declines ODDS (%) | 7 days ago 51% | 20 days ago 58% |
| BollingerBands ODDS (%) | 4 days ago 52% | 4 days ago 65% |
| Aroon ODDS (%) | 4 days ago 53% | 4 days ago 59% |
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.36% | ||
| BMY - PFE | 60% Loosely correlated | +0.38% | ||
| MRK - PFE | 55% Loosely correlated | -0.10% | ||
| AMGN - PFE | 53% Loosely correlated | -1.42% | ||
| NVS - PFE | 51% Loosely correlated | +0.67% | ||
| BIIB - PFE | 51% Loosely correlated | -1.40% | ||
More | ||||